

DAFTAR PUSTAKA

- Abou-Zied, H.A., Beshr, E.A.M., Hayallah, A.M., and Abdel-Aziz, M., 2024, Emerging insights into pyrazoline motifs: A comprehensive exploration of biological mechanisms and prospects for future advancements, *J. Mol. Struct.*, 1296, 136807.
- Ahsan, M.J., Ali, A., Ali, A., Thiriveedhi, A., Bakht, M.A., Yusuf, M., Salahuddin, Afzal, O., and Altamimi, A.S.A., 2022, Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders, *ACS Omega*, 7, 38207-38245.
- Aksoz, B.E., and Ertan, R., 2012, Spectral properties of chalcones II, *J. Pharm. Sci.*, 37, 205–216.
- Alidmat, M.M., Khairuddean, M., Norman, N.M., Asri, A.N.M., Suhaimi, M.H.M., and Sharma, G., 2021, Synthesis, characterization, docking study and biological evaluation of new chalcone, pyrazoline, and pyrimidine derivatives as potent antimalarial compounds, *Arab. J. Chem.*, 14, 103304.
- Amin, K.M., Eissa, A.A.M., Abou-Seri, S.M., Awadallah, F.M., and Hassan, G.S., 2013, Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitumor agents, *Eur. J. Med. Chem.*, 60, 187–198.
- Amewu, R.K., Sakyi, P.O., Osei-Safo, D., and Addae-Mensah, I., 2021, Synthetic and naturally occurring heterocyclic anticancer compounds with multiple biological targets, *Molecules*, 26, 7134.
- Anand, U., Dey, A., Chandel, A.K.S., Sanyal, R., Mishra, A., Pandey, D.K., Falco, V.D., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J.K., Dewanjee, S., Vallamkondu, J., and Lastra, J.M.P., 2023, Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics, *Genes Dis.*, 10, 1367–1401.
- Anonim, 2024^a, *Cancer incident in the world*, International Agency for Research on Cancer, World Health Organization, Lyon.
- Anonim, 2024^b, *Cancer incident in Indonesia*, International Agency for Research on Cancer, World Health Organization, Lyon.
- Archna, Pathania, S., and Chawla, P.A., 2020, Thiophene-based derivatives as anticancer agents: An overview on decade's work, *Bioorg. Chem.*, 101, 104026.
- Behranvand, N., Nasri, F., Emmameh, Z., Khani, P., Hosseini, A., Garssen, J., and Falak, R., 2022, Chemotherapy: A double-edged sword in cancer treatment, *Cancer Immunol. Immunother.*, 71, 507–526.

- Bhandare, R.R., Munkrishnappa, C.S., Kumar, G.V.S., Konidala, S.K., Sigalapalli, D.K., Vaishnav, Y., Chinnam, S., Yasin, H., Al-karmalawy, A.A., and Shaik, A.B., 2022, Multistep synthesis and screening of heterocyclic tetrads containing furan, pyrazoline, thiazole and triazole (or oxadiazole) as antimicrobial and anticancer agents, *J. Saudi Chem. Soc.*, 26, 101447.
- Blagosklonny, M.V., 2023, Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells, *Oncotarget*, 14, 193–206.
- Bukowski, K., Kciuk, M., and Kontek, R., 2020, Mechanisms of multidrug resistance in cancer chemotherapy, *Int. J. Mol. Sci.*, 21, 3233.
- Chatzopoulou, M., 2021, Bioisosterism in drug discover, *Bioorganic Med. Chem.*, 108, 117758.
- Chen, Y., Tortorici, M.A., Garrett, M., Hee, B., Klamerus, K.J., and Pithavala, Y.K., 2013, Clinical pharmacology of axitinib, *Clin. Pharmacokinet.*, 52, 713–725.
- Chen, W., Caceres-Cortes, J., Zhang, H., Zhang, D., Humphreys, W.G., and Gan, J., 2011, Bioactivation of substituted thiophenes including α -chlorothiophene-containing compounds in human liver microsomes, *Chem. Res. Toxicol.*, 24, 663–669.
- Chhikara, B.S., and Parang, K., 2023, Global cancer statistics 2022: The trends projection analysis, *Chem. Biol. Lett*, 10, 451.
- Chunaifah, I., Venilita, R.E., Tjitda, P.J.P., Astuti, E., and Wahyuningsih, T.D., 2024, Thiophene-based *N*-phenyl pyrazolines: synthesis, anticancer activity, molecular docking and ADME study, *J. Appl. Pharm. Sci.*, 14, 63–71.
- Dalvie, D.K., Kalgutkar, A.S., Khojasteh-bakht, S.C., Obach, R.S., and O'Donnell, J.P., 2002, Biotransformation reactions of five-membered aromatic heterocyclic rings, *Chem. Res. Toxicol.*, 15, 269–299.
- Davodabadi, F., Sajjadi, S.F., Sarhadi, M., Mirghasemi, S., Hezaveh, M.N., Khosravi, S., Andani, M.K., Cordani, M., Basiri, M., and Ghavami, S., 2023, Cancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery, *Eur. J. Pharmacol.*, 958, 176013.
- Edrees, M.M., Abu-Melha, S., Saad, A.M., Kheder, N.A., Gomha, S.M., and Muhammad, Z.A., 2018, Eco-friendly synthesis, characterization and biological evaluation of some novel pyrazolines containing thiazole moiety as potential anticancer and antimicrobial agents, *Molecules*, 23, 2970.
- Elewa, S.I., Mansour, E., Nassar, I.F., and Mekawey, A.A.I., 2020, Synthesis of some new pyrazoline-based thiazole derivatives and evaluation of their antimicrobial, antifungal, and anticancer activities, *Russ. J. Bioorganic Chem.*, 46, 382–392.

- de Farias, I.F., Gonçalves, R. de O., de Freitas, M.D., da Silva, F.L., de Sousa, A.F., Trevisan, M.T.S., Lomonaco, D., Monte, F.J.Q., da Fonseca, A.M., and de Lemos, T.L.G., 2023, Synthesis, characterization and molecular docking study of pyrazolines synthesized from chalcones: Antioxidant and acetylcholinesterase activities, *J. Mol. Struct.*, 1291, 1–10.
- Farooq, S., and Ngaini, Z., 2020, Synthesis, molecular docking and antimicrobial activity of α,β -unsaturated ketone exchange moiety for chalcone and pyrazoline derivatives, *ChemistrySelect*, 5, 9974–9979.
- Feng, S., and Chien, S., 2003, Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases, *Chem. Eng. Sci.*, 58, 4087–4114.
- Ghasemi, M., Turnbull, T., Sebastian, S., and Kempson, I., 2021, The MTT assay: Utility, limitations, pitfalls, and interpretation in bulk and single-cell analysis, *Int. J. Mol. Sci.*, 22, 12827.
- Ghifari, T.A., Wulan, F.F., Astuti, E., Suryanti, V., Putri, D.E.K., Nur, H., and Wahyuningsih, T.D., 2025, Synthesis of furan-based pyrazoline as an anticancer agent: An *in vitro* and *in silico* approach toward COX-2 inhibition, *J. Mol. Struct.*, 1337, 142125.
- Gielecinska, A., Kciuk, M., Yahya, E.-B., Ainane, T., Mujwar, S., and Kontek, R., 2023, Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?, *Biochim Biophys Acta Rev Cancer*, 1878, 189024.
- Gomes, M.N., Muratov, E.N., Pereira, M., Peixoto, J.C., Rosseto, L.P., Cravo, P.V.L., Andrade, C.H., and Neves, B.J., 2017, Chalcone derivatives: Promising starting points for drug design, *Molecules*, 22, 1210.
- Hamad, H.T., 2025, The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom, *Results Chem.*, 15, 102182.
- Haider, K., Shafeeqe, M., Yahya, S., and Yar, M.S., 2022, A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents, *Eur. J. Med. Chem.*, 5, 100042.
- Hanahan, D., and Weinberg, R.A., 2011, Hallmarks of cancer: The next generation, *Cell*, 144, 646–674.
- Hanahan, D., and Weinberg, R.A., 2000, The hallmarks of cancer, *Cell*, 100, 57–70.
- Hawaiz, F.E., Hussain, F.H.S., and Azeez, H.J., 2014, Synthesis and characterization of some new 5-[2,4-di(4-chlorobenzyloxy)phenyl]-3-(4-substituted phenyl)-2-pyrazolines, *J. Mater. Sci. Eng.*, 11, 361–366.

- Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., and Sarkar, S., 2014, Drug resistance in cancer: An overview, *Cancers.*, 6, 1769–1792.
- Ioffe, B.V., 1968, Characteristic frequencies in the infrared spectra of pyrazolines, *Chem. Heterocycl. Compd.*, 4, 1089–1092.
- Jarag, K.J., Pinjari, D.V., Pandit, A.B., and Shankarling, G.S., 2011, Synthesis of chalcone (3-(4-fluorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one): Advantage of sonochemical method over conventional method, *Ultrason. Sonochem.*, 18, 617–623.
- Karabacak, M., Altintop, M.D., Çiftçi, H.I., Koga, R., Otsuka, M., Fujita, M., and Özdemir, A., 2015, Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents, *Molecules*, 20, 19066-19084.
- Karthikeyan, M.S., Holla, B.S., and Kumari, N.S., 2007, Synthesis and antimicrobial studies on novel chloro-fluorine containing hydroxy pyrazolines, *Eur. J. Med. Chem.*, 42, 30–36.
- Khanam, H., Parveen, S., Gautam, A.K., Gupta, A.K., Banerjee, M., Pandey, J., Singh, M., Rao, D.P., Maurya, R.K., Gautam, A.K., Maurya, H.K., and Gautam, Y., 2025, Synthesis, crystallographic, spectroscopic, quantum chemical studies and anticancer activity of novel pyrazoline derivative, *J. Mol. Struct.*, 25, 142742.
- Lima, L.M., and Barreiro, E.J., 2005, Bioisosterism: A useful strategy for molecular modification and drug design, *Cur. Med. Chem.*, 12, 23-49.
- Lodhi, G.N., Nayak, A., and Jain, A.P., 2021, Chemical and pharmacological evolution of some synthesized chalcones and heterocyclic compounds, *Int. J. Adv. Res. Ideas Innov. Technol.*, 7, 2130–2172.
- Matiadis, D., and Sagnou, M., 2020, Pyrazoline hybrids as promising anticancer agents: An up-to-date overview, *Int. J. Mol. Sci.*, 21, 5507.
- Matthews, H.K., Bertoli, C., and de Bruin, R.A.M., 2022, Cell cycle control in cancer, *Nat. Rev. Mol. Cell Biol.*, 23, 74–88.
- Meerlo, J.V., Kaspers, G.J.L., and Cloos, J., 2011, *Cancer cell culture*, Springer, New York.
- Mezgebe, K., Melaku, Y., and Mulugeta, E., 2023, Synthesis and pharmacological activities of chalcone and its derivatives bearing N-heterocyclic scaffolds: A review, *ACS Omega*, 8, 19194–19211.
- Mohammed, N., Mulugeta, E., Garg, A., and Tadesse, A., 2024, Synthesis, molecular docking studies, and evaluation of antibacterial and antioxidant activities of pyrazoline derivatives, *Results Chem.*, 24, 101570.
- Mohsin, N.A., Aslam, S., Ahmad, M., Irfan, M., Al-Hussain, S.A., and Zaki, M.E.A., 2022, Cyclooxygenase-2 (COX-2) as a target of anticancer agents: A

- review of novel synthesized scaffolds having anticancer and COX-2 inhibitory potentialities, *Pharmaceuticals*, 15, 1471.
- Mostavi, M., Chiu, Y.C., Huang, Y., and Chen, Y., 2020, Convolutional neural network models for cancer type prediction based on gene expression, *BMC Med. Genomics*, 13, 44.
- Mulugeta, D., 2022, A review of synthesis methods of chalcones, flavonoids, and coumarins, *Sci. J. Chem.*, 10, 41–52.
- Mustofa, M., Satriyo, P.B., Suma, A.A.T., Waskitha, S.S.W., Wahyuningsih, T.D., and Sholikhah, E.N., 2022, A potent EGFR inhibitor, *N*-phenyl pyrazoline derivative suppresses aggressiveness and cancer stem cell-like phenotype of cervical cancer cells, *Drug Des. Devel. Ther.*, 16, 2325–2339.
- Nehra, B., Rulhania, S., Jaswal, S., Kumar, B., Singh, G., and Monga, V., 2020, Recent advancements in the development of bioactive pyrazoline derivatives, *Eur. J. Med. Chem.*, 205, 112666.
- Niles, A.L., Moravec, R.A., and Riss, T.L., 2008, Update on *in vitro* cytotoxicity assays for drug development, *Expert Opin. Drug Discov.*, 3, 655–669.
- Noblejas-López, M.d.M., Tébar-García, D., López-Rosa, R., Alcaraz-Sanabria, A., Cristóbal-Cueto, P., Pinedo-Serrano, A., Rivas-García, L., and Galán-Moya, E.M., 2023, TACKling cancer by targeting selective protein degradation, *Pharmaceuticals*, 15, 2442.
- Ouyang, Y., Li, J., Chen, X., Fu, X., Sun, S., and Wu, Q., 2021, Chalcone derivatives: Role in anticancer therapy, *Biomolecules*, 11, 894.
- Patani, G.A., and LaVoie, E.J., 1996, Bioisosterism: A rational approach in drug design, *Chem. Rev.*, 96, 3147-3176.
- Prabhudeva, M.G., Bharath, S., Kumar, A.D., Naveen, S., Lokanath, N.K., Mylarappa, B.N., and Kumar, K.A., 2017, Design and environmentally benign synthesis of novel thiophene appended pyrazole analogues as anti-inflammatory and radical scavenging agents: Crystallographic, *in silico* modeling, docking and SAR characterization, *Bioorg. Chem.*, 73, 109–120.
- Qin, Y., Li, Y., Jiang, A., Yang, M., Zhu, Q., Dong, H., and Zhu, H., 2015, Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors, *Eur. J. Med. Chem.*, 94, 447-457.
- Rammohan, A., Reddy, J.S., Sravya, G., Rao, C.N., and Zyryanov, G. V., 2020, Chalcone synthesis, properties and medicinal applications: A review, *Environ. Chem. Lett.*, 18, 433–458.
- Rana, M., Arif, R., Khan, F.I., Maurya, V., Singh, R., Faizan, M.I., Yasmeen, S., Dar, S.H., Alam, R., Sahu, A., Ahmad, T., and Rahisuddin, 2021, Pyrazoline analogs as potential anticancer agents and their apoptosis, molecular docking,

- MD simulation, DNA binding and antioxidant studies, *Bioorg. Chem.*, 108, 104665.
- Ratnawati, D., Kartini, I., Pranowo, H.D., Kurniawan, Y.S., and Wahyuningsih, T.D., 2024, Enhancement of the sensitivity of chalcone derived from vanillin as chemosensor agents for Hg(II) ions through cyclization reaction with arylhydrazine, *Chinese J. Anal. Chem.*, 52, 4811.
- Sahu, N.K., Balbhadra, S.S., Choudhary, J., and Kohli, D.V., 2012, Exploring pharmacological significance of chalcone scaffold: A review, *Curr. Med. Chem.*, 19, 209–225.
- Samota, M.K., Yadav, D.K., Koli, P., Kaur, M., Kaur, M., Rani, H., Selvan, S.S., Mahala, P., Tripathi, K., and Kumar, S., 2024, Exploring natural chalcones: Innovative extraction techniques, bioactivities, and health potential, *Sustain. Food Technol.*, 2, 1456–1468.
- Sethy, C., and Kundu, C.N., 2021, 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: Implications of DNA repair inhibition, *Biomed. Pharmacother.*, 137, 111285.
- Sever, B., Altintop, M.D., Radwan, M.O., Özdemir, A., Otsuka, M., Fujita, M., and Ciftci, H.I., 2019, Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors, *Eur. J. Med. Chem.*, 182, 111648.
- Sharma, P., Yusuf, M., and Malik, A.K., 2024, Pyrazoline-based fluorescent probe: Synthesis, characterization, theoretical simulation, and detection of picric acid, *J. Fluoresc.*, 34, 1851–1864.
- Siegel, R.L., Miller, K.D., Fuchs, H.E., and Jemal, A., 2022, Cancer statistics, 2022, *CA. Cancer J. Clin.*, 72, 7–33.
- Silverstein, R.M., Webster, F.X., and Kiemle, D.J., 2005, *Spectrometric Identification of Organic Compounds*, 7th ed. John Wiley & Sons, Inc., New York.
- Sivaiah, G., Raveesha, R., Prasad, S.B.B., Kumar, K.Y., Raghu, M.S., Alharethy, F., Prashanth, M., and Jeon, B.H., 2023, Synthesis, anticancer activity and molecular docking of new pyrazolo [1,2- α]pyrimidine derivatives as EGFR/HER2 dual kinase inhibitors, *J. Mol. Struct.*, 1289, 135877.
- Stockert, J.C., Blázquez-Castro, A., Cañete, M., Horobin, R.W., and Villanueva, Á., 2012, MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets, *Acta Histochem.*, 114, 785–796.
- Suma, A.A.T., and Wahyuningsih, T.D., 2023, Study of 1-formyl-2-pyrazolines as anticancer drug candidates, *Indones. J. Pharm.*, 34, 630–639.

- Suma, A.A.T., Wahyuningsih, T.D., and Mustofa, 2019^a, Efficient synthesis of chloro chalcones under ultrasound irradiation, their anticancer activities and molecular docking studies, *Rasayan J. Chem.*, 12, 502–510.
- Suma, A.A.T., Wahyuningsih, T.D., and Mustofa, 2019^b, Synthesis, cytotoxicity evaluation and molecular docking study of *N*-phenylpyrazoline derivatives, *Indones. J. Chem.*, 19, 1081–1090.
- Suma, A.A.T., Wahyuningsih, T.D., and Pranowo, D., 2017, Synthesis and antibacterial activities of *N*-phenylpyrazolines from veratraldehyde, *Mater. Sci. Forum*, 901, 124–132.
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., and Bray, F., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, *CA. Cancer J. Clin.*, 71, 209–249.
- Suyambulingam, A., Nair, S., and Chellapandian, K., 2022, Synthesis, spectral characterization of novel chalcones based oxazines derivatives and screening of their antimicrobial and antioxidant activity, *J. Mol. Struct.*, 1268, 133708.
- Swanepoel, B., Nitulescu, G.M., Oлару, O.T., Venables, L., and van de Venter, M., 2019, Anti-cancer activity of a 5-aminopyrazole derivative lead compound (BC-7) and potential synergistic cytotoxicity with cisplatin against human cervical cancer cells, *Int. J. Mol. Sci.*, 20, 5559.
- Tan, S., Li, D., and Zhu, X., 2020, Cancer immunotherapy: Pros, cons and beyond, *Biomed. Pharmacother.*, 124, 109821.
- Tanamatayarat, P., Limtrakul, P., Chunsakaow, S., and Duangrat, C., 2003, Screening of some rubiaceae plants for cytotoxic activity against Cervix Carcinoma (KB-3-1) cell line, *J. Pharm. Sci.*, 27, 167–172.
- Tunjung, W.A.S., and Sayekti, P.R., 2019, Apoptosis induction on human breast cancer T47D cell line by extracts of *Ancorina sp.*, *F1000Research*, 8, 168.
- Upadhyay, A., 2021, Cancer: An unknown territory; Rethinking before going ahead, *Genes Dis.*, 8, 655–661.
- Wahyuningsih, T.D., Setiawati, Suma, A.A.T., Stansyah, Y.M., and Astuti, E., 2022, Synthesis, biological evaluation and molecular docking of methoxy *N*-phenylpyrazoline derivatives as anticancer agents, *Pak. J. Pharm. Sci.*, 35, 965–972.
- Wei, G., Wang, Y., Yang, G., Wang, Y., and Ju, R., 2021, Recent progress in nanomedicine for enhanced cancer chemotherapy, *Theranostics*, 11, 6370–6392.
- Wilhelm, A., Bonnet, S.L., Twigge, L., Rarova, L., Stenclova, T., Visser, H.G., and Schutte-Smith, M., 2022, Synthesis, characterization and cytotoxic evaluation of chalcone derivatives, *J. Mol. Struct.*, 1251, 132001.

- Wulan, F.F., Wahyuningsih, T.D., Astuti, E., and Prasetyo, N., 2024, Towards targeting EGFR and COX-2 inhibitors: Comprehensive computational studies on the role of chlorine group in novel thienyl-pyrazoline derivative, *J. Biomol. Struct. Dyn.*, 42, 8.
- Wulan, F.F., 2025, *In silico* design, synthesis, and molecular mechanism of chlorothiophene-based chalcone and pyrazoline derivatives as anticancer agents, *Dissertation*, Department of Chemistry, Universitas Gadjah Mada, Yogyakarta.
- Yadav, C.S., Azad, I., Khan, A.R., Nasibullah, M., Ahmad, N., Hansda, D., Ali, S.N., Shrivastav, K., Akil, M., and Lohani, M.B., 2024, Recent advances in the synthesis of pyrazoline derivatives from chalcones as potent pharmacological agents: A comprehensive review, *Results Chem.*, 7, 101326.
- Yu, M., Yang, H., Wu, K., Ji, Y., Ju, L., and Lu, X., 2014, Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma, *Bioorganic Med. Chem.*, 22, 4109-4118.
- Zhao, M., Cui, Y., Zhao, L., Zhu, T., Lee, R.J., Liao, W., Sun, F., Li, Y., and Teng, L., 2019, Thiophene derivatives as new anticancer agents and their therapeutic delivery using folate receptor-targeting nanocarriers, *ACS Omega*, 4, 8874–8880.
- Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., and Miao, Z., 2017, Chalcone: A privileged structure in medicinal chemistry, *Chem. Rev.*, 117, 7762–7810.